Taiho Pharmaceutical's news releases are intended to provide information to the media. It may contain information about ethical drugs or products under development, however information contained in the news releases are not intended to constitute promotion, advertisement, or medical advice.
Site search
2013
November 11, 2013
Phase III Clinical Trial Results of TS-1 on Metastatic Colorectal Cancer Published in Digital Version of The Lancet Oncology
September 25, 2013
Cancer Pain Reliever E-fen Buccal Tablets Launched
September 11, 2013
Results of a Clinical Trial (JACCRO GC-05) of Second-line TS-1 Therapy on Patients with Unresectable or Recurrent Gastric Cancer That Is Refractory to Initial Therapy with TS-1
June 21, 2013
Anticancer Agent TS-1 Combination OD Tablets T20, T25 to Be Launched in Japan
June 06, 2013
Results of Phase III Trials of TS-1 on Patients with Colorectal Cancer and Head and Neck Cancers Announced at ASCO®
May 24, 2013
New Plant Constructed in Tokushima Prefecture
April 03, 2013
Results of the Phase III Clinical Study (GEST) of TS-1 in Patients with Advanced Pancreatic Cancer Published in the Online Version of the Journal of Clinical Oncology
February 27, 2013
Taiho Pharmaceutical Submits Application for Approval to Manufacture and Market Novel Antitumor Agent TAS-102
February 21, 2013
Antitumor Agent "ABRAXANE® I.V. Infusion 100 mg" Approved for Additional Indications of Gastric Cancer and Non-small Cell Lung Cancer
February 13, 2013
Condition for Approval (All-Patient Enrollment)of ABRAXANE® I.V. Infusion 100mg Antineoplastic Removed
January 28, 2013
Resected Pancreatic Cancer Announced at the Gastrointestinal Cancers Symposium of the American Society of Clinical Oncology
News Releases
Select year from the Back Number
Back Number
2019
2018
2017
2016
2015
2014
2013
2012
2011
2010
2009
2008
